PERFORM Publications

Keyword search (4,163 papers available)

Title		Authors	PubMed ID
1	Human short-term memory learning based on dynamic glutamate levels and oscillatory activities: concurrent metabolic and electrophysiological studies using event-related functional-MRS and EEG modalities	Mohammadi H; Zargaran SJ; Khajehpour H; Adibi I; Rahimiforoushani A; Karimi S; Serej ND; Alam NR;	41171530 PERFORM
2	Syngap1 regulates the synaptic drive and membrane excitability of Parvalbumin-positive interneurons in mouse auditory cortex	Francavilla R; Chattopadhyaya B; Damo Kamda JL; Jadhav V; Kourrich S; Michaud JL; Di Cristo G;	40810392 CSBN
3	Depression, Estrogens, and Neuroinflammation: A Preclinical Review of Ketamine Treatment for Mood Disorders in Women	Gagne C; Piot A; Brake WG;	35115970 CSBN
4	Amyloid-β (1-42) peptide induces rapid NMDA receptor-dependent alterations at glutamatergic synapses in the entorhinal cortex	Olajide OJ; Chapman CA;	34144329 PSYCHOLOGY
5	Hippocampal Degeneration and Behavioral Impairment During Alzheimer-Like Pathogenesis Involves Glutamate Excitotoxicity.	Olajide OJ, Gbadamosi IT, Yawson EO, Arogundade T, Lewu FS, Ogunrinola KY, Adigun OO, Bamisi O, Lambe E, Arietarhire LO, Oluyomi OO, Idowu OK, Kareem R, Asogwa NT, Adeniyi PA	33420680 PSYCHOLOGY
6	Ventral Midbrain NMDA Receptor Blockade: From Enhanced Reward and Dopamine Inactivation.	Hernandez G, Cossette MP, Shizgal P, Rompré PP	27616984 PSYCHOLOGY
7	Repeated ventral midbrain neurotensin injections sensitize to amphetamine-induced locomotion and ERK activation: A role for NMDA receptors.	Voyer D, Lévesque D, Rompré PP	27267684 CSBN
8	Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.	DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E	27578494 PERFORM

Title:	Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.
Authors:	DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E
Link:	https://www.ncbi.nlm.nih.gov/pubmed/27578494?dopt=Abstract
DOI:	10.1093/cercor/bhw249
Publication:	Cerebral cortex (New York, N.Y. : 1991)
Keywords:	[11C]ABP688; epilepsy; focal cortical dysplasia; metabotropic glutamate receptor type 5; positron-emission tomography;
PMID:	27578494	Category:	Cereb Cortex	Date Added:	2019-04-15
Dept Affiliation:	PERFORM 1 Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, 3801 University Street, Montreal, Quebec, Canada H3A 2B4. 2 Division of Nuclear Medicine and Molecular Imaging, Johns Hopkins University, Baltimore, MD 21287, USA. 3 Department of Pathology, McGill University, Montreal, Quebec, Canada H3A 2B4. 4 PET Unit, McConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada H3A 2B4. 5 Division of Imaging Sciences and Biomedical Engineering, King's College London, St. Thomas' Hospital, London SE1 7EH, UK. 6 Bio-Imaging Group, PERFORM Centre, Concordia University, Montreal, Quebec, Canada H4B 1R6. 7 Translational Neuroimaging Laboratory, McGill Center for Studies in Aging, Douglas Mental Health University Institute, McGill University, Montreal, Quebec, Canada H4H 1R3.

Description:

Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.

Cereb Cortex. 2016 10 17;26(11):4170-4179

Authors: DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E

Abstract

Metabotropic glutamate receptor type 5 (mGluR5) abnormalities have been described in tissue resected from epilepsy patients with focal cortical dysplasia (FCD). To determine if these abnormalities could be identified in vivo, we investigated mGluR5 availability in 10 patients with focal epilepsy and an MRI diagnosis of FCD using positron-emission tomography (PET) and the radioligand [11C]ABP688. Partial volume corrected [11C]ABP688 binding potentials (BPND) were computed using the cerebellum as a reference region. Each patient was compared to homotopic cortical regions in 33 healthy controls using region-of-interest (ROI) and vertex-wise analyses. Reduced [11C]ABP688 BPND in the FCD was seen in 7/10 patients with combined ROI and vertex-wise analyses. Reduced FCD BPND was found in 4/5 operated patients (mean follow-up: 63 months; Engel I), of whom surgical specimens revealed FCD type IIb or IIa, with most balloon cells showing negative or weak mGluR5 immunoreactivity as compared to their respective neuropil and normal neurons at the border of resections. [11C]ABP688 PET shows for the first time in vivo evidence of reduced mGluR5 availability in FCD, indicating focal glutamatergic alterations in malformations of cortical development, which cannot be otherwise clearly demonstrated through resected tissue analyses.

PMID: 27578494 [PubMed - indexed for MEDLINE]

BookR: School of Health Core Facilities Booking

"glutamate" Keyword-tagged Publications:

Search Publications

No results